Cargando…

Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A

BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosada, Rogério S., Moreira, Ana P., Frantz, Fabiani G., Puri, Raj K., Rahman, Aquilur, Standiford, Theodore J., Zárate-Bladés, Carlos R., Silva, Célio L., Hogaboam, Cory M.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806906/
https://www.ncbi.nlm.nih.gov/pubmed/20090941
http://dx.doi.org/10.1371/journal.pone.0008721
_version_ 1782176347992358912
author Rosada, Rogério S.
Moreira, Ana P.
Frantz, Fabiani G.
Puri, Raj K.
Rahman, Aquilur
Standiford, Theodore J.
Zárate-Bladés, Carlos R.
Silva, Célio L.
Hogaboam, Cory M.
author_facet Rosada, Rogério S.
Moreira, Ana P.
Frantz, Fabiani G.
Puri, Raj K.
Rahman, Aquilur
Standiford, Theodore J.
Zárate-Bladés, Carlos R.
Silva, Célio L.
Hogaboam, Cory M.
author_sort Rosada, Rogério S.
collection PubMed
description BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. The aim of the present study was to determine whether the presence of an immune response to P. aeruginosa and/or its exotoxin A (PE) would diminish the anti-fibrotic properties of IL13-PE. METHODOLOGY/PRINCIPAL FINDINGS: Fourteen days after P. aeruginosa infection, C57BL/6 mice were injected with bleomycin via the intratracheal route. Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t. with bleomycin 28 days later. At day 21 after bleomycin, all mice received either saline vehicle or IL13-PE by the intranasal route and histopatological analyses of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary P. aeruginosa infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Although prior intranasal administration of IL13-PE failed to elicit an antibody response, the systemic administration of IL13-PE induced a strong neutralizing antibody response. However, the prior systemic sensitization of mice with IL13-PE did not inhibit the anti-fibrotic effect of IL13-PE in fibrotic mice. CONCLUSIONS: Thus, IL13-PE therapy in pulmonary fibrosis works regardless of the presence of a humoral immune response to Pseudomonas exotoxin A. Interestingly, a prior infection with P. aeruginosa markedly attenuated the pulmonary fibrotic response suggesting that the immune elicitation by this pathogen exerts anti-fibrotic effects.
format Text
id pubmed-2806906
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28069062010-01-21 Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A Rosada, Rogério S. Moreira, Ana P. Frantz, Fabiani G. Puri, Raj K. Rahman, Aquilur Standiford, Theodore J. Zárate-Bladés, Carlos R. Silva, Célio L. Hogaboam, Cory M. PLoS One Research Article BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. The aim of the present study was to determine whether the presence of an immune response to P. aeruginosa and/or its exotoxin A (PE) would diminish the anti-fibrotic properties of IL13-PE. METHODOLOGY/PRINCIPAL FINDINGS: Fourteen days after P. aeruginosa infection, C57BL/6 mice were injected with bleomycin via the intratracheal route. Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t. with bleomycin 28 days later. At day 21 after bleomycin, all mice received either saline vehicle or IL13-PE by the intranasal route and histopatological analyses of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary P. aeruginosa infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Although prior intranasal administration of IL13-PE failed to elicit an antibody response, the systemic administration of IL13-PE induced a strong neutralizing antibody response. However, the prior systemic sensitization of mice with IL13-PE did not inhibit the anti-fibrotic effect of IL13-PE in fibrotic mice. CONCLUSIONS: Thus, IL13-PE therapy in pulmonary fibrosis works regardless of the presence of a humoral immune response to Pseudomonas exotoxin A. Interestingly, a prior infection with P. aeruginosa markedly attenuated the pulmonary fibrotic response suggesting that the immune elicitation by this pathogen exerts anti-fibrotic effects. Public Library of Science 2010-01-15 /pmc/articles/PMC2806906/ /pubmed/20090941 http://dx.doi.org/10.1371/journal.pone.0008721 Text en Rosada et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rosada, Rogério S.
Moreira, Ana P.
Frantz, Fabiani G.
Puri, Raj K.
Rahman, Aquilur
Standiford, Theodore J.
Zárate-Bladés, Carlos R.
Silva, Célio L.
Hogaboam, Cory M.
Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title_full Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title_fullStr Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title_full_unstemmed Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title_short Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
title_sort therapeutic efficacy of cintredekin besudotox (il13-pe38qqr) in murine lung fibrosis is unaffected by immunity to pseudomonas aeruginosa exotoxin a
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806906/
https://www.ncbi.nlm.nih.gov/pubmed/20090941
http://dx.doi.org/10.1371/journal.pone.0008721
work_keys_str_mv AT rosadarogerios therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT moreiraanap therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT frantzfabianig therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT purirajk therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT rahmanaquilur therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT standifordtheodorej therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT zaratebladescarlosr therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT silvaceliol therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina
AT hogaboamcorym therapeuticefficacyofcintredekinbesudotoxil13pe38qqrinmurinelungfibrosisisunaffectedbyimmunitytopseudomonasaeruginosaexotoxina